• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Editorial: Shaping of Human Immune System and Metabolic Processes by Viruses and Microorganisms
Conclusions In conclusion, articles in this Research Topic made a very significant contribution to our understanding of the role played by environmental factors, dysbiotic conditions, and infections in triggering diseases. Since this is a rapidly expanding area of research, many other factors contributing to the onset of these diseases are not covered here. We are confident, however, that further studies will expand the list as well as bring a better understanding of mechanisms involved in the onset of autoimmune and autoinflammatory diseases. Author Contributions All authors listed have made a substantial, direct and i...
Source: Frontiers in Microbiology - April 16, 2019 Category: Microbiology Source Type: research

Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
This study was carried out in accordance with the recommendations of The London School of Hygiene & Tropical Medicine (LSHTM) Research Ethics Committee (Ref. 6123) and the National Research Ethics Service (NRES) London-Bloomsbury Research Ethics Committee (REC ref. 11/10/1760, IRAS ID: 77765), with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the LSHTM Research Ethics Committee and the NRES London-Bloomsbury Research Ethics Committee. Author Contributions JC, HD, LN, EL, and ER devised the study ...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells
This study was provided by the Canadian Institutes of Health Research and the Manitoba Health Research Council. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. References 1. Sprent J, Kishimoto H. The thymus and central tolerance. Philos Trans R Soc Lond B Biol Sci. (2001) 356:609–16. doi: 10.1098/rstb.2001.0846 PubMed Abstract | CrossRef Full Text | Google Scholar 2. Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and perspective...
Source: Frontiers in Immunology - April 8, 2019 Category: Allergy & Immunology Source Type: research

Clinical Spectrum of Patients with Pathogenic Variant of STAT3 conferring Gain-of-Function: A Mimic of Autoimmune Lymphoproliferative Syndrome
Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder caused by defective fas-mediated apoptosis. Patients often present in childhood with lymphoproliferation, splenomegaly and multilineage cytopenias (Price et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 2014). Though mutations in the FAS gene account for the majority of cases, an estimated 20% of patients who have no defined genetic cause are classified as ALPS-U (Shah et al. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Current allergy and asthma reports 20...
Source: Blood - November 21, 2018 Category: Hematology Authors: Constantine, G., Su, H., Folio, L., Milner, J., Rao, V. K. Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III Source Type: research

The Role of Vitamin D on Circulating Memory T Cells in Children: The Generation R Study
ConclusionsOur results suggest that vitamin D enhances cellular immunity in young children.This article is protected by copyright. All rights reserved.
Source: Pediatric Allergy and Immunology - July 7, 2017 Category: Allergy & Immunology Authors: Kirsten I.M. Looman, Michelle A.E. Jansen, Trudy Voortman, Diana den Heuvel, Vincent W.V. Jaddoe, Oscar H. Franco, Menno C. van Zelm, Henri ëtte A. Moll Tags: Original Article Source Type: research

Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A  pilot study
Atopic dermatitis (AD) is a relapsing condition prone to infections such as herpes simplex virus, resulting in AD with eczema herpeticum (ADEH), a more severe clinical manifestation.1 Recent medical research has implicated vitamin D (VD) in AD.2,3 It appears essential for skin barrier structure, increasing profilaggrin and lipid lamella production.4 Of interest is the effect of VD on the expression of antimicrobial peptide LL-37,3 which demonstrates significant antiviral activity against herpes simplex virus, and immune-modifying characteristics.
Source: Journal of Allergy and Clinical Immunology - July 12, 2016 Category: Allergy & Immunology Authors: Lujain H. Albenali, Simon Danby, Manar Moustafa, Kirsty Brown, John Chittock, Fiona Shackley, Michael J. Cork Tags: Letter to the Editor Source Type: research

Recent advances in epidemiology and prevention of atopic eczema
This article is protected by copyright. All rights reserved.
Source: Pediatric Allergy and Immunology - November 19, 2014 Category: Allergy & Immunology Authors: Francesca Cipriani, Arianna Dondi, Giampaolo Ricci Tags: Review Source Type: research

An expert system for the diagnosis and management of oral ulcers
Publication date: April 2014 Source:Tanta Dental Journal, Volume 11, Issue 1 Author(s): Sh.A. Ali , H.I. Saudi The present research was conducted to introduce a Visual Basic expert system to help the postgraduate students in the diagnosis and treatment of the most common and rare oral ulcers. A total of sixty postgraduate students shared in the study. They received the system on a CD-ROM and asked to evaluate it using a printed questionnaire. The oral ulcerative conditions merged in the database included, aphthous ulcers, chancre, traumatic ulcers, histoplasmosis ulcers, acute herpetic ulcers, burns, herpangina, tubercul...
Source: Tanta Dental Journal - November 6, 2014 Category: Dentistry Source Type: research